PARIS, France, March 12 /CNW Telbec/ - At the plenary "Society &
Politics" session of the BioVision 2007 forum - The Global Forum on Science &
Life - Jean-François DEHECQ, President of the sanofi-aventis Group laid out a
series of major achievements of the "Access to Medicine" Policy in the
Southern Hemisphere. He covered six major focuses:
- 5 therapeutic areas, namely malaria, tuberculosis, sleeping sickness,
leishmaniasis and epilepsy - as well as vaccines.
This policy was presented by Jean-François DEHECQ during his talk at the
closing session of the BioVision 2005 forum.
In a world in which 80% of the population has little or no access to the
most basic medicines (especially in the Southern Hemisphere where there are no
social healthcare systems), the sanofi-aventis Group, notably its Access to
Medicines Division, is developing concrete operations to make access to health
care a central element in the Group's global strategy.
The remit of the sanofi-aventis Access to Medicines Division is to
instigate and coordinate the Group's activities in the fight against certain
diseases which represent major public health problems and in which the Group
possesses real acknowledged expertise. The strategy is centered around three
- differential pricing policies
- ongoing development of existing medicines
- information, education and communication campaigns targeting all
This commitment has resulted in concrete achievements:
- malaria: research and development for new antimalarial drugs; the
development of new formulations and combinations based on existing
modalities; information, education and communication campaigns
targeting all parties concerned by the disease; and the establishment
of special pricing policies and distribution networks.
- tuberculosis: the development of new therapeutic protocols and active
participation in the Tuberculosis Free program in South Africa-
associated with the regrouping of our worldwide antituberculous drug
production capacities in that country.
- sleeping sickness: renewal of our partnership with the WHO focusing on
diagnosis and drug supply.
- leishmaniasis: making medicines available with a differential pricing
system - "no profit no loss" - and centralization of production in
- epilepsy: launching of a training program in Mali for general
practitioner in the most remote rural regions, and extension to other
- vaccines: provision of vaccines to international organizations for the
eradication of poliomyelitis and immunization against yellow fever;
continuation of a research program into dengue fever; and establishment
of a differential pricing policy within the framework of a partnership
with the Global Alliance for Vaccines and Immunization (GAVI).
"All of these initiatives are being undertaken voluntarily and in keeping
with the historic heritage of the sanofi-aventis Group. This is our duty as a
major international player in the field of pharmaceuticals and vaccines,
backed by a talent for innovation, competitive industrial facilities and a
willingness to continue making the most of our mature older quality products"
said Jean-François DEHECQ.
"As manufacturers too, we are dedicated to making our contribution to
economic growth in the southern hemisphere, and we are doing all we can to
keep our industrial facilities running in those countries. It is there that
the pharmaceutical industry is playing for its future and, if it fails to meet
the challenges, it will no longer exist" he concluded.
Sanofi-aventis is one of the world leaders in the pharmaceutical
industry, ranking number one in Europe. Backed by a world-class R&D
organisation, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases,
central nervous system, internal medicine and vaccines. Sanofi-aventis is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
are statements that are not historical facts. These statements include
financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives and expectations with respect to future
events, operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the words
"expect," "anticipates," "believes," "intends," "estimates," "plans" and
similar expressions. Although sanofi-aventis' management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for
the year ended December 31, 2005. Other than as required by applicable law,
sanofi-aventis does not undertake any obligation to update or revise any
forward-looking information or statements.
For further information:
For further information: Robert SEBBAG, +33 (0)1 41 24 57 78, +33 (0)6
08 17 21 83; Michel Labie, Senior Vice President, Corporate Communications;
Jean-Marc Podvin, Vice President, Media Relations, +33 220.127.116.11.23; Salah
Mahyaoui, Vice President, Product Communications, +33 18.104.22.168.31;